Logo

Management Protocol for Patients with Oral Cancers at A Tertiary Centre

PDF

Published: December, 2024

Keywords: Oral cavity cancer, Systemic therapy

Author
  • Suman Das
  • Sayantan Nag
  • Dipsankar Jana
  • Ranjan Raychowdhury
Abstract

Management of oral cancers involves a multidisciplinary team approach. Surgery is ideally the primary treatment option for non­ metastatic disease, and less invasive curative surgical approaches are preferred in earlystage disease to minimize surgical morbidity. For patients at high risk of recurrence, adjuvant treatment using radiation therapy or chemoradiation is often used. Systemic therapy may also be used in the neoadjuvant setting (for advanced-stage disease with the intent of mandibular preservation) or in the palliative setting (for non-salvageable locoregional recurrence and/or distant metastases). Patient involvement in treatment decision is the key for patient-driven management, particularly in clinical situation with poor prognosis, for example, early postoperative recurrence before planned adjuvant therapy.

Reference
  1. Sung H, Ferlay J, Siegel RL, et al: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021.
  2. Badwelan M, Muaddi H, Ahmed A: Oral squamous cell carcinoma and concomitant primary tumors: What do we know? A review of the literature. Curr Oncol 30:3721-3734, 2023.
  3. Hashibe M: Risk factors for cancer of the mouth: Tobacco, betel quid, and alcohol, in Wamakulasuriya S, Greenspan J (eds): Textbook of Oral Cancer [Textbooks in Contemporary Dentistry]. Cham, Switzerland, Springer, 2020, pp 23-30.
  4. Heller MA, Nyirjesy SC, Balsiger R, et al: Modifiable risk factors for oral cavity cancer in non-smokers: A systematic review and meta-analysis. Oral Oncol 137:106300, 2023.
  5. Leemans CR, Parmar S: Surgical management of oral cavity cancer, in Vermorken Jet al (eds): Critical Issues in Head and Neck Oncology. Cham, Switzerland, Springer, 2018, pp 67-73.
  6. Crile, G. Landmark article I December 1906: Excision of cancer of the head and neck. With special reference to the plan of dissection based on one hundred and thirty-two operations. By George Crile. JAMA 1987, 258, 3286-3293.
  7. Inchingolo, F.; Santacroce, L.; Ballini, A.; Topi, S.; Dipalma, G.; Haxhirexha, K.; Bottalico, L.; Charitos, I.A. Oral Cancer : A Historical Review. Int. J. Environ. Res. Public Health 2020, 17, 3168.
  8. Van Baar, G.J.C.; Forouzanfar, T.; Liberton, N.; Winters, H.A.H.; Leusink, F.K.J. Accuracy of computer-assisted surgery in mandibular reconstruction: A systematic review. Oral Oneal. 2018, 84, 52-60
  9. Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; et al. Outcomes and prognostic factors for squamous cell carcinoma of the oral tongne in young adults: A single-institution case-matched analysis. Eur. Arch. Otorhinolaryngol. 2017, 274, 1683-1690.
  10. Brennan, P.A.; Bradley, K.L.; Brands, M. Intensity­ modulated radiotherapy in head and neck cancer - An update for oral and maxillofacial surgeons. Br. J. Oral Maxillofac. Surg. 2017, 55, 770-774.
  11. Patil, V.M.; Noronha, V.; Joshi, A.; Abhyankar, A.; Menon, N.; Dhumal, S.; Prabhash, K. Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. Oral Oneal. 2020, 105, 104673.
  12. Xu, Y.; Wen, N.; Sonis, S.T.; Villa, A. Oral side effects of immune checkpoint inhibitor therapy (!CIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer 2021, 127, 1796-1804.
  13. Moore, K.A.; Ford, P.J.; Farah, C.S. Support needs and quality of life in oral cancer: A systematic review. Int. J Dent. Hyg. 2014, 12, 36-47.
  14. Friedlander, A.H.; Rosenbluth, S.C.; Rubin, R.T. The adult suicide-prone patient: A review of the medical literature and implications for oral and maxillofacial surgeons. J. Oral Maxillofac. Surg. 2012, 70, 1253-1260.
  15. Twigg, J.A.; Anderson, J.M.; Humphris, G.; Nixon, I.; Rogers, S.N.; Kanatas, A. Best practice in reducing the suicide risk in head and neck cancer patients: A structured review. Br. J. Oral Maxillofac. Surg. 2020, 58, e6-el5.
  16. Stenson KM, Kunnavakkam R, Cohen EEW, Portugal LD, Blair E, HarafDJ, et al. Chemoradiation for patients with advanced oral cavity cancer. The Laryngoscope. 2010;120( I):93-9.
  17. Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, et al. Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol 2018;80:16-22
  18. Licitra L, Grandi C, Guzzo M, Mariani L, Vullo SL, Valvo F, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003;21(2):327-33.
  19. Zhong L, Zhang C, Ren G, Guo W, William WN, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and tluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Onco 2013;31(6):744-51
  20. Sanyal SD, Sinha Roy D, Sengupta M, Ray P, Sarkar K, Das S, Raychowdhury R. The Joint Head & Neck Clinic at the Vivekananda Institute of Medical Sciences. J Vivek Inst of Med Sci 2021;44(11):10-14.

Archives

June, 2024
Journal of The Vivekananda Institute of Medical Sciences, Vol. 47 ( I )

Vol. 47 No. I

June, 2024
Unsafe CSOM with Post-auricular Abscess in Patients with Microtia : Our Experience

Vol. 47 No. I

June, 2024
Selective Microdochectomy in Management of Single Duct Pathological Nipple Discharge : A Case Series

Vol. 47 No. I